Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed

Executive Summary

The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.

You may also be interested in...



Medicines Patent Pool Unveils New Approach To Drug Candidate Selection

The Medicines Patent Pool has developed a new prioritization framework to identify promising drug candidates for in-licensing, including in the antibiotics area, after its scope was expanded beyond its initial target areas. Later this year it also plans to look at whether its licensing model could be adapted to biologic medicines.

UK Attacks Pandemic With Funding For Drug And Vaccine Trials

Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125269

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel